Bavituximab: Phase Ib started

Peregrine said investigators at the University of Texas Southwestern Medical Center began an open-label, U.S. Phase Ib trial of 3 mg/kg IV bavituximab in up to 24 patients. Patients will receive weekly bavituximab for 2 weeks followed by weekly bavituximab for 12 additional weeks plus 3 mg/kg IV Yervoy ipilimumab every 3 weeks for up to 4 cycles or Yervoy for 4 cycles. ...